July 21, 2020
NAGASE & Co., Ltd.

Business Alliance with Karydo TherapeutiX Begins:
Using AI to Predict with High Precision the Effects and Side Effects ofPharmaceuticals and Food Products on the Human BodyPredictions can be made based on the body’s reactions alone, without information on thecomposition of the product being tested

NAGASE & Co., Ltd. (Chuo-ku, Tokyo; Representative Director and President: Kenji Asakura) has begun
its business alliance with Karydo TherapeutiX, Inc. (Chiyoda-ku, Tokyo; Chair of Board of Directors:
Thomas N. Sato), which develops and provides services using big data and AI to predict the effects on thehuman body of pharmaceuticals, food products, and agrochemicals.
NAGASE provides the pharmaceutical industry with finish dosage form, pharmaceutical active ingredients,
and intermediates and additives for compounding, while providing the food industry with functional foodmaterials, and has a large customer network. A problem in these industries is that the increasing length oftime required for the certification of new compounds which could lead to new active ingredients orfunctionality has caused a corresponding increase in development costs.
Karydo’s core technology is an algorithm that decodes the multidimensional crosstalk network between
organs in the body upon the intake of pharmaceuticals or food products. For example, by imputing thereactions of various organs in the body which occur upon administering a pharmaceutical (such aschanged numerical values), and carrying out mathematical, information, and AI analysis, it is possible topredict the effects and side effects of the pharmaceutical even without information on its composition.
Another benefit is that unlike a black box AI in which it is not possible to see the process by which a resultis reached, this is a transparent white box AI which shows the mechanisms by which the effects and side
effects of the pharmaceutical occur.
With this technology, new drug targets (active sites) can be predicted in less time, and the success rate ofclinical trials for new drugs increased, which should contribute to shortening the process required fordeveloping new drugs. Additionally, if new biomarkers and targets for diagnosis can be found in less time,
this will lead to new possibilities in the medical approaches taken for disease prevention or treatment inpre-symptomatic stages. Through this business alliance, NAGASE has acquired exclusive worldwide
marketing rights for the fundamental technologies developed by Karydo. By applying these technologies
in pharmaceuticals, food products, and other fields, we will contribute to building “a sustainable world
where people live with peace of mind.”■Outline of Karydo TherapeutiX, Inc.
(1) Name

Karydo TherapeutiX, Inc.

(2) Head Office

Chiyoda-ku, Tokyo(3) Representative

Chair of Board of Directors Thomas N. Sato

(4) Established2015(5) Business AreasDevelopingandproviding

technologyplatforms

allowingfor

identification/prevention, pre-emptive treatment, and control of disease(6) URL

https://karydo-tx.com/■Inquiries
NAGASE & CO., LTD.
Contact for BusinessLife & Healthcare Products Department, Pharma-Medicals Division
Tel: 06-6535-2327
Contact for News Reporting
Corporate Planning Department, Corporate Administration OfficeTel: 03-3665-3640

early